Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation

[1]  S. Wisniewski,et al.  Plasma and cerebrospinal fluid α1‐antichymotrypsin levels in Alzheimer's disease: Correlation with cognitive impairment , 2003, Annals of neurology.

[2]  L. Mucke,et al.  Modulation of Alzheimer-Like Synaptic and Cholinergic Deficits in Transgenic Mice by Human Apolipoprotein E Depends on Isoform , Aging, and Overexpression of Amyloid β Peptides But Not on Plaque Formation , 2002, The Journal of Neuroscience.

[3]  S. Paul,et al.  Apolipoprotein E alters the processing of the β-amyloid precursor protein in APPV717F transgenic mice , 2002, Brain Research.

[4]  J. Poirier,et al.  Apolipoprotein E knockout mice display procedural deficits in the Morris water maze: analysis of learning strategies in three versions of the task , 2002, Neuroscience.

[5]  Markus Rudin,et al.  Compromised Hemodynamic Response in Amyloid Precursor Protein Transgenic Mice , 2002, The Journal of Neuroscience.

[6]  Bruce J Aronow,et al.  Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Xin Wu,et al.  Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model , 2002, Nature Neuroscience.

[8]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[9]  A. Fagan,et al.  Human and Murine ApoE Markedly Alters Aβ Metabolism before and after Plaque Formation in a Mouse Model of Alzheimer's Disease , 2002, Neurobiology of Disease.

[10]  Brett Chromy,et al.  Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus , 2002, Brain Research.

[11]  Saumya Das,et al.  Effect of cytokines, dexamethazone and the A/T-signal peptide polymorphism on the expression of alpha1-antichymotrypsin in astrocytes: significance for Alzheimer's disease , 2001, Neurochemistry International.

[12]  H. Potter,et al.  The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation , 2001, Neurobiology of Aging.

[13]  D. Diamond,et al.  Behavioral assessment of Alzheimer's transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory. , 2001, DNA and cell biology.

[14]  S. Paul,et al.  Neuroinflammation‐induced acceleration of amyloid deposition in the APPV717F transgenic mouse , 2001, The European journal of neuroscience.

[15]  M. Sasamata,et al.  Apolipoprotein E deposition and astrogliosis are associated with maturation of β-amyloid plaques in βAPPswe transgenic mouse: Implications for the pathogenesis of Alzheimer’s disease , 2001, Brain Research.

[16]  D. Diamond,et al.  Correlation between cognitive deficits and Aβ deposits in transgenic APP+PS1 mice , 2001, Neurobiology of Aging.

[17]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[18]  S. Paul,et al.  α-1-Antichymotrypsin Promotes β-Sheet Amyloid Plaque Deposition in a Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.

[19]  D. Diamond,et al.  Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes , 2001, Brain Research.

[20]  J. Hardy,et al.  Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.

[21]  Guiquan Chen,et al.  A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease , 2000, Nature.

[22]  J. Hardy,et al.  Pathways to Primary Neurodegenerative Disease , 2000, Annals of the New York Academy of Sciences.

[23]  J. Poirier,et al.  Apolipoprotein E and Alzheimer's Disease A Role in Amyloid Catabolism , 2000, Annals of the New York Academy of Sciences.

[24]  L. Mucke,et al.  Astroglial expression of human alpha(1)-antichymotrypsin enhances alzheimer-like pathology in amyloid protein precursor transgenic mice. , 2000, The American journal of pathology.

[25]  Hsiao-Wen Chen,et al.  Unusual spectral energy distribution of a galaxy previously reported to be at redshift 6.68 , 2000, Nature.

[26]  D. Selkoe,et al.  The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. , 2000, Biochemistry.

[27]  K. Ashe,et al.  Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease , 2000, The Journal of Neuroscience.

[28]  W. Griffin,et al.  Interleukin‐1 and the Immunogenetics of Alzheimer Disease , 2000, Journal of neuropathology and experimental neurology.

[29]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[30]  A. Fagan,et al.  Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Dodart,et al.  Behavioral deficits in APPV717F transgenic mice decient for the apolipoprotein E gene , 2000, Neuroreport.

[32]  S. Paul,et al.  Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Jim J. Hagan,et al.  Use of SHIRPA and discriminant analysis to characterise marked differences in the behavioural phenotype of six inbred mouse strains , 1999, Behavioural Brain Research.

[34]  J. Sloane,et al.  Metalloendopeptidase EC 3.4.24.15 Is Necessary for Alzheimer’s Amyloid-β Peptide Degradation* , 1999, The Journal of Biological Chemistry.

[35]  E. Masliah,et al.  Synaptic alterations in apolipoprotein E knockout mice , 1999, Neuroscience.

[36]  C. Cahill,et al.  Translation of the Alzheimer Amyloid Precursor Protein mRNA Is Up-regulated by Interleukin-1 through 5′-Untranslated Region Sequences* , 1999, The Journal of Biological Chemistry.

[37]  J. Gilbert,et al.  Specific regional transcription of apolipoprotein E in human brain neurons. , 1999, The American journal of pathology.

[38]  C. Lukacs,et al.  Alzheimer’s Peptide Aβ1–42 Binds to Two β-Sheets of α1-Antichymotrypsin and Transforms It from Inhibitor to Substrate* , 1998, The Journal of Biological Chemistry.

[39]  T. Wisniewski,et al.  The prionoses and other conformational disorders. , 1998, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[40]  E. Masliah,et al.  Increased levels of α-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype , 1998, Journal of Neuroimmunology.

[41]  E. Otomo,et al.  Association of α1‐antichymotrypsin polymorphism with cerebral amyloid angiopathy , 1998 .

[42]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  H. Potter,et al.  The essential role of inflammation and induced gene expression in the pathogenic pathway of Alzheimer's disease. , 1998, Frontiers in bioscience : a journal and virtual library.

[44]  T. Bliss,et al.  Behavioural, physiological and morphological analysis of a line of apolipoprotein E knockout mouse , 1998, Neuroscience.

[45]  S. Paul,et al.  Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition , 1997, Nature Genetics.

[46]  D. Walsh,et al.  Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. , 1997, The Journal of biological chemistry.

[47]  J. Wehner,et al.  Assessment of learning by the Morris water task and fear conditioning in inbred mouse strains and F1 hybrids: implications of genetic background for single gene mutations and quantitative trait loci analyses , 1997, Neuroscience.

[48]  G. Higgins,et al.  Absence of central cholinergic deficits in ApoE knockout mice , 1997, Psychopharmacology.

[49]  J. Hardy,et al.  Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.

[50]  J. Rogers,et al.  Relative efficacies of amyloid β peptide (Aβ) binding proteins in Aβ aggregation , 1996 .

[51]  H. Brewer,et al.  Alzheimer Aβ neurotoxicity: Promotion by antichymotrypsin, ApoE4; inhibition by Aβ-related peptides , 1996, Neurobiology of Aging.

[52]  C. Lukacs,et al.  Is the binding of β‐amyloid protein to antichymotrypsin in Alzheimer plaques mediated by a β‐strand insertion? , 1996 .

[53]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[54]  M. Mullan,et al.  β-Amyloid-mediated vasoactivity and vascular endothelial damage , 1996, Nature.

[55]  Steven A. Johnson,et al.  Clusterin (apoJ) Alters the Aggregation of Amyloid β-Peptide (Aβ1-42) and Forms Slowly Sedimenting Aβ Complexes That Cause Oxidative Stress , 1995, Experimental Neurology.

[56]  F. Cohen,et al.  Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein , 1995, Cell.

[57]  M. Ilyas Kamboh,et al.  A4POE*4-associated Alzheimer's disease risk is modified by α1–antichymotrypsin polymorphism , 1995, Nature Genetics.

[58]  A D Roses,et al.  Apolipoprotein E and Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[59]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[60]  Saumya Das,et al.  Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1 , 1995, Neuron.

[61]  H. Brewer,et al.  Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments , 1994, Nature.

[62]  T Vogel,et al.  Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. , 1994, The American journal of pathology.

[63]  A. Roses,et al.  Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. , 1994, The Journal of clinical investigation.

[64]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[65]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[66]  G. Forloni,et al.  Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: modulation by interleukin-1. , 1992, Brain research. Molecular brain research.

[67]  P. Greengard,et al.  Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[68]  B. Cooperman,et al.  Crystallization, activity assay and preliminary X-ray diffraction analysis of the uncleaved form of the serpin antichymotrypsin. , 1992, Journal of molecular biology.

[69]  Thomas Wisniewski,et al.  Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid , 1992, Neuroscience Letters.

[70]  E. Otomo,et al.  Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease , 1991, Brain Research.

[71]  P. Mcgeer,et al.  Anti-inflammatory drugs and Alzheimer disease , 1990, The Lancet.

[72]  H. W. Harris,et al.  Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[73]  D. Selkoe,et al.  Immunochemical identification of the serine protease inhibitor α 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease , 1988, Cell.

[74]  R. Morris,et al.  Place navigation impaired in rats with hippocampal lesions , 1982, Nature.

[75]  D. Price,et al.  Mutant genes in familial Alzheimer's disease and transgenic models. , 1998, Annual review of neuroscience.

[76]  Peter T. Lansbury,et al.  Observation of metastable Aβ amyloid protofibrils by atomic force microscopy , 1997 .